Cura Therapeutics
Cura Therapeutics is pioneering the next generation of multimodal immunotherapies to treat cancer and age-associated diseases, aiming to improve healthspan and increase longevity. Their innovative approach involves developing best/first-in-class immunotherapies that engage multiple immune system mechanisms to combat diseases such as metastatic cancers, infections, fibrotic diseases, and senescence. Their lead immunotherapy, CT101, is a multimodal recombinant protein designed to activate immune responses, reduce tumor microenvironment suppression, and disrupt tumor blood supply, offering a promising new treatment for metastatic cancer. The company actively seeks strategic partnerships to develop and commercialize these therapies.
Industries
Nr. of Employees
small (1-50)
Cura Therapeutics
Montréal, Quebec, Canada, North America
Patents
Method of reducing or treating fibrosis by administering an interleukin-2/TGF-beta receptor fusion polypeptide
US-12329803-B2
View DetailsMulti-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
US-12258383-B2
View DetailsPharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
US-11701334-B2
View DetailsMethod of treating or ameliorating a pathogenic infection by administering an interleukin-2/TGF-β receptor fusion polypeptide
US-11672844-B2
View DetailsMulti-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
US-11407814-B2
View Details
Method of reducing or treating fibrosis by administering an interleukin-2/TGF-beta receptor fusion polypeptide
US-12329803-B2
View DetailsMulti-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
US-12258383-B2
View DetailsPharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
US-11701334-B2
View DetailsMethod of treating or ameliorating a pathogenic infection by administering an interleukin-2/TGF-β receptor fusion polypeptide
US-11672844-B2
View DetailsMulti-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
US-11407814-B2
View DetailsProducts
Lead multimodal recombinant protein immunotherapy (lead candidate)
A multifunctional recombinant fusion protein candidate designed to activate and synchronize immune mechanisms, promote immune effector activation and tumor infiltration, reduce immunosuppressive tumor microenvironment elements, and disrupt tumor vasculature to limit growth and spread; developed for treatment of metastatic cancer and other age-associated diseases.
CT Discovery Platform
CURA's novel CT discovery platform harnesses the healing power of the immune system by leveraging AI predictive protein modeling, comprehensive immune functional assays, and deep domain expertise in pathway analysis to design bioengineered recombinant proteins that initiate a sequence of immune responses to combat complex diseases.
CT101
Cura's lead immunotherapy is a multimodal recombinant protein that activates and synchronizes major immune system mechanisms to destroy cancer cells, reduce immunosuppression, and disrupt tumor blood supply.
Lead multimodal recombinant protein immunotherapy (lead candidate)
A multifunctional recombinant fusion protein candidate designed to activate and synchronize immune mechanisms, promote immune effector activation and tumor infiltration, reduce immunosuppressive tumor microenvironment elements, and disrupt tumor vasculature to limit growth and spread; developed for treatment of metastatic cancer and other age-associated diseases.
CT Discovery Platform
CURA's novel CT discovery platform harnesses the healing power of the immune system by leveraging AI predictive protein modeling, comprehensive immune functional assays, and deep domain expertise in pathway analysis to design bioengineered recombinant proteins that initiate a sequence of immune responses to combat complex diseases.
CT101
Cura's lead immunotherapy is a multimodal recombinant protein that activates and synchronizes major immune system mechanisms to destroy cancer cells, reduce immunosuppression, and disrupt tumor blood supply.
Services
Strategic collaboration agreements with pharmaceutical and biotechnology companies to develop and commercialize multifunctional fusion protein immunotherapies.
Strategic collaboration agreements with pharmaceutical and biotechnology companies to develop and commercialize multifunctional fusion protein immunotherapies.
Expertise Areas
- Immunotherapy development
- Recombinant fusion protein engineering
- Immuno-oncology (metastatic cancers)
- Anti-angiogenesis and anti-metastatic therapeutics
Key Technologies
- Recombinant protein engineering
- Fusion protein platforms
- Immune modulation strategies
- Anti-angiogenesis biologics